Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | APP | P05067 | 17/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134443 | 0.86 | IDO1 (0.46) | IDO1APP | |
| SCHEMBL13622041 | 0.80 | CYP3A4 (0.54) | CYP3A4IDO1APP | |
| SCHEMBL20987949 | 0.79 | IDO1 (0.38) | CYP3A4IDO1APP | |
| SCHEMBL22711528 | 0.79 | PTGS2 (0.41) | CYP3A4IDO1APP | |
| SCHEMBL8020885 | 0.78 | ESR1 (0.48) | CYP3A4IDO1APP | |
| SCHEMBL508682 | 0.78 | CYP3A4 (0.64) | CYP3A4IDO1APP | |
| SCHEMBL9679767 | 0.78 | TSHR (0.52) | IDO1APP | |
| SCHEMBL198803 | 0.78 | ERN1 (0.47) | IDO1 | |
| SCHEMBL11310162 | 0.78 | ESR1 (0.48) | CYP3A4IDO1APP | |
| SCHEMBL12378 | 0.76 | AGXT (0.61) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8176049-A | — | — | None | — | — | JP | disclosed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| EP-4230621-A1 | SUBSTITUTED N-BENZOIC ACID URACILS, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer AG (DE) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230620-A1 | SUBSTITUTED N-AMINO-N-BENZOIC ACID URACILS, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023107563-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023016521-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| US-20210169911-A1 | PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5'-NUCLEOTIDASE INHIBITORS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-10 | — | — | US | disclosed |
| US-11008324-B2 | — | — | 2021-05-18 | — | — | US | disclosed |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20110092668-A1 | AZIDE FUNCTIONALIZED PEPTIDE TARGETING GROUPS | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110021718-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | INTEZYNE TECHNOLOGIES (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2077266-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-08 | — | — | EP | disclosed |
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | MSD K.K. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-5945501-A | Epoxy resin compositions including novel phenol novolak condensates produced from bis(methoxymethyl)biphenyls | UBE INDUSTRIES, LTD. (JP) | 1999-08-31 | — | — | US | disclosed |
| US-5612442-A | Phenol novolak condensate and bis(methoxymethyl)biphenyl for production thereof | UBE INDUSTRIES, LTD. (JP) | 1997-03-18 | — | — | US | disclosed |
| JP-H08176049-A | PRODUCTION OF METHOXYMETHYLIODOBENZENE | UBE IND LTD | 1996-07-09 | — | — | JP | disclosed |
| EP-0003261-B1 | OXADITHIADIAZAPENTALENES, THEIR PREPARATION, FUNGICIDAL COMPOSITIONS CONTAINING THEM AND THE CONTROL OF FUNGI USING THEM | CHEVRON RESEARCH COMPANY (US) | 1981-12-30 | — | — | EP | disclosed |
| US-4179441-A | REACTING SULFUR HALIDE WITH N-CYANOMETHYLCARBOXAMIDE; CYCLIZATION | CHEVRON RESEARCH COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
| EP-0003261-A1 | Oxadithiadiazapentalenes, their preparation, fungicidal compositions containing them and the control of fungi using them | CHEVRON RESEARCH COMPANY (US) | 1979-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | CYP3A4 662/4885IDO1 1260/4885APP 2620/4885 |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | CYP3A4 4736/4885IDO1 4046/4885APP 3530/4885 |
| US-11008324-B2 | — | RET, GFRA1, GFRA2 | CYP3A4 4870/4885IDO1 3860/4885APP 3884/4885 |
| US-20110092668-A1 | AZIDE FUNCTIONALIZED PEPTIDE TARGETING GROUPS | IAPP, NGLY1, MSN | CYP3A4 4782/4885IDO1 2687/4885APP 105/4885 |
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | GCKR, GCK, GPR119 | CYP3A4 1668/4885IDO1 3950/4885APP 4715/4885 |
| US-20210169911-A1 | PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5'-NUCLEOTIDASE INHIBITORS | NUDT1, NTPCR, NT5C2 | CYP3A4 3981/4885IDO1 375/4885APP 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.